Skip to main content

The ALPHA Project

The Addressing Lupus Pillars for Health Advancement (ALPHA) Project is a unique global consensus initiative that seeks to identify and prioritize the fundamental barriers or knowledge gaps, that will allow providers, researchers, and scientists to improve the diagnosis, treatment, and systems of care for people with lupus.

ALPHA will be carried out in two phases. Phase 1 is underway and is expected to wrap up in December 2018.

Alt text

The Global Advisory Committee, a team of 13 lupus experts from around the world, leads the ALPHA Project and brings expertise in patient advocacy, lupus research, drug development, rheumatology, nephrology, and dermatology.

Global Advisory Committee Members

  • Kathleen Arntsen | Lupus and Allied Diseases Association, Inc., U.S.
  • Sang-Cheol Bae, MD, PhD, MPH | Hanyang University, South Korea
  • Ian Bruce, MD, FRCP | University of Manchester, U.K.
  • Karen Costenbader, MD, MPH | Brigham and Women’s Hospital, U.S.
  • Thomas Dörner, MD | Charité University, Germany
  • Amy Kao, MD, MPH, MS | EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany)
  • Sue Manzi, MD | Allegheny Health Network, U.S.
  • Eric Morand, MBBS (Hons), FRACP, PhD | Monash University, Australia
  • Sandra Raymond | Lupus Foundation of America, U.S.
  • Brad Rovin, MD, FACP, FASN | Ohio State University, U.S.
  • Laura Schanberg, MD | Duke University Medical Center, U.S.
  • Joan Von Feldt, MD, MSEd | GlaxoSmithKline, U.S.
  • Victoria Werth, MD | University of Pennsylvania and Philadelphia VAMC, U.S.


ALPHA is supported by founding partner EMD Serono and through additional support by GSK. If you are a pharmaceutical company interested in supporting the ALPHA Project or would like to receive the ALPHA Newsletter, please contact Donna Grogan at [email protected].